HDAC inhibitors have been reported to reduce the levels of TNF, IL-1α, IL-1β, and IFN-γ in LPS-stimulated normal PBMC and reduce the levels of proinflammatory cytokines such as TNF and IL-6 in PBMC of RA patients [1, 24, 26, 28]. Here, IFNG is linked to rheumatoid arthritis.